Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri

Gel Gets Backing Of The EMA

24 May 2021

Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.

Barcelona is home to Almirall • Source: Archive

Klisyri has got off to a good start in the US and Almirall SA is now getting ready for launch in Europe, having received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the Spanish company's actinic keratosis therapy.

Klisyri (tirbanibulin), a novel microtubule inhibitor, has been backed by the European Medicines Agency for the topical treatment of actinic keratosis of the face or scalp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.